Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 19;20(1):45.
doi: 10.1186/s12904-021-00735-0.

Opioid therapy vs. multimodal analgesia in head and neck Cancer (OPTIMAL-HN): study protocol for a randomized clinical trial

Sondos Zayed  1 , Pencilla Lang  1 , Lucas C Mendez  1 , Nancy Read  1 , Jinka Sathya  1 , Varagur Venkatesan  1 , Dwight E Moulin  2 , Andrew Warner  1 , David A Palma  3
Affiliations

Opioid therapy vs. multimodal analgesia in head and neck Cancer (OPTIMAL-HN): study protocol for a randomized clinical trial

Sondos Zayed et al. BMC Palliat Care. .

Abstract

Background: Radiation-induced mucositis (RIM) pain confers substantial morbidity for head and neck cancer (HNC) patients undergoing radiotherapy alone (RT) or chemoradiotherapy (CRT), often reducing treatment compliance. However, no standard currently exists for the treatment of RIM, and high dose opioid therapy, with its associated side effects and increased risk for chronic opioid use, remains the cornerstone of HNC pain management. The goal of this randomized clinical trial is to compare multimodal analgesia using analgesic medications with different mechanisms of action, to the institutional standard of opioid analgesia alone, in order to ascertain the optimal analgesic regimen for the management of RIM pain in HNC patients.

Methods: In this open-label, single-institution, non-inferiority, randomized clinical trial, sixty-two patients with mucosal head and neck malignancies treated with curative-intent radiation will be randomized in a 1:1 ratio, stratified by RT or CRT, between Arm 1: opioid analgesia alone as per the institutional standard, or Arm 2: multimodal analgesia using Pregabalin, Acetaminophen, and Naproxen, in addition to opioids, if required. The primary endpoint is the average 11-Numeric Rating Scale (11-NRS) score for pain during the last week of radiation treatment. Secondary endpoints include: average weekly opioid use, duration of opioid requirement, average daily 11-NRS score for pain, average weekly opioids dispensed, quality of life, hospitalizations for analgesic medication-induced complications, time to feeding tube insertion, weight loss, toxicity, treatment interruptions, and death within 3 months of completing RT treatment. Patients are eligible once analgesia is required for moderate 4/10 pain.

Discussion: This study will assess the efficacy and safety of multimodal analgesia and its impact on opioid requirements, clinical outcomes, and quality of life, as a potential new standard treatment for RIM pain in HNC patients undergoing definitive RT or CRT.

Trial registration: ClinicalTrials.gov Identifier: NCT04221165 . Date of registration: January 9, 2020. Appendix 2 reports the World Health Organization trial registration dataset.

Keywords: Head and neck Cancer; Multimodal analgesia; Non-inferiority; Opioid analgesia; Radiation Mucositis; Radiotherapy; Randomized clinical trial.

PubMed Disclaimer

Conflict of interest statement

None to declare from the study sponsor/PIs or any study investigators.

Figures

Fig. 1
Fig. 1
Study Schema. Abbreviations: RT – radiotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ing JW. Head and neck Cancer pain. Otolaryngol Clin N Am. 2017;50(4):793–806. doi: 10.1016/j.otc.2017.04.001. - DOI - PubMed
    1. Elad S, Yarom N. The search for an effective therapy and pain relief for Oral Mucositis. Jama. 2019;321(15):1459–1461. doi: 10.1001/jama.2019.3269. - DOI - PubMed
    1. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–1461. doi: 10.1002/cncr.28592. - DOI - PMC - PubMed
    1. M V-L, G O, M H, S S. Oral Mucositis in Patients Undergoing Radiation Treatment for Head and Neck Carcinoma. Cancer. 2006;106(2). - PubMed
    1. Mirabile A, Airoldi M, Ripamonti C, Bolner A, Murphy B, Russi E, et al. Pain management in head and neck cancer patients undergoing chemo-radiotherapy: clinical practical recommendations. Crit Rev Oncol Hematol. 2016;99:100–106. doi: 10.1016/j.critrevonc.2015.11.010. - DOI - PubMed

Publication types

Substances

Associated data